Page 30 - Immune Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23), MarketWatch Earnings reports. Alpine Immune Sciences had a negative return on equity of 58.85% and a negative net margin of 169.03%. Shares […]

<p><span>Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on&nbsp;</span><span class="xn-chron">Monday, December 20, 2021</span><span>.</span></p>

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior

Alpine Immune Sciences will move a potential treatment for immune conditions into human testing and support its ongoing trials for cancer thanks to around $91…

Biogen isn't the only company whose shares should benefit from a breakthrough drug.